MedTrace Logo

Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone

NCT04097158 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2025-05-21

No results posted yet for this study

Summary

This study is being conducted to help the investigators better understand how the new FDA approved medication Edaravone (also known as Radicava) works in subsets of patients with ALS. The investigators are also trying to understand if there are specific ALS patients, with different presentations of ALS, who might benefit most from this medication. Also, the investigators are following specific biomarkers to determine the optimal treatment duration in patients with different forms of ALS

There is no study medication being offered in this trial. Edaravone is prescribed as part of regular care. In this trial we are collecting blood, urine, and spinal fluid samples in ALS patients who are taking Edaravone and ALS patients who are not taking Edaravone to measure certain markers that could indicate why the drug may be working in a specific type of ALS.

Conditions

Interventions

OTHER

Sample Collection

The investigators will be collecting blood, urine, and spinal fluid samples.

Sponsors & Collaborators

  • Temple University

    collaborator OTHER

  • Thomas Jefferson University

    collaborator OTHER

  • University of Southern California

    collaborator OTHER

  • Northwestern University

    collaborator OTHER

  • Loma Linda University

    lead OTHER

Principal Investigators

  • Jeffrey Rosenfeld, PhD, MD · Loma Linda University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-08
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04097158 on ClinicalTrials.gov